• FDA advisory panel backed approval of Grail’s Galleri multi-cancer early detection blood test for adults aged 50 and older.
• Panel voted 7-2, with 1 abstention, that benefits outweigh risks; safety vote was unanimous; effectiveness vote was 6-4.
• FDA final decision on the PMA is expected in the coming months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grail Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609231817PR_NEWS_USPR_____LA55764) on September 23, 2026, and is solely responsible for the information contained therein.